Dr. Gilberto Lopes Brought on Board at Immorta Bio
Immorta Bio Inc., a pioneering longevity company focused on advancing scientific understanding of aging and its related diseases, has appointed Dr. Gilberto de Lima Lopes Jr., MD, MBA, FAMS to its Strategic Advisory Board. With a commitment to treating diseases of aging, Immorta Bio is set to revolutionize therapeutic strategies.
A Path to Clinical Trials for Innovative Immunotherapy
The company is actively collaborating with the FDA to propel its innovative senolytic immunotherapy, known as SenoVax™, into clinical trials specifically aimed at treating non-small cell lung cancer (NSCLC). This step signifies a significant progression towards developing groundbreaking therapies that target cancer effectively.
A Leader in Lung Cancer and Immunotherapy
Dr. Lopes has garnered international recognition for his extensive experience and leadership in lung cancer research and the emerging field of immuno-oncology. He has played a crucial role as the principal investigator of KEYNOTE-042, a pivotal trial that laid the groundwork for the FDA's first-line approval of pembrolizumab (Keytruda) for patients with PD-L1-positive advanced NSCLC. His career has fundamentally altered the landscape of lung cancer treatment, providing access to advanced immunotherapy to hundreds of thousands of patients globally.
Welcoming a Medical Pioneer
Boris N. Reznik, PhD, the Chairman and CEO of Immorta Bio, expressed enthusiasm about Dr. Lopes' appointment. "We are honored to welcome a medical pioneer who helped bring game-changing immunotherapy to lung cancer. With Dr. Lopes' guidance, we aim to deliver the next leap—senolytic immunotherapy—to patients who urgently need new options," Reznik stated. This collaboration signifies a bright future for Immorta Bio and the patients it serves.
Advancing SenoVax™ and Its Promise
Immorta Bio's lead program, SenoVax™, is a first-of-its-kind senolytic immunotherapy that aims to empower the immune system to selectively target and eliminate senescent cells. These aged, dysfunctional cells often accumulate in tumors, impeding effective immune response and treatment outcomes. Early preclinical studies reveal that SenoVax™ exhibits promising anti-tumor activity across a variety of solid tumor models, including those prevalent in lung, breast, glioma, and pancreatic cancers. The therapeutic also shows potential synergy when combined with traditional checkpoint inhibitors.
Creating a Synergistic Effect
Dr. Thomas E. Ichim, PhD, President and Chief Scientific Officer at Immorta Bio, emphasized the significance of SenoVax™ in modern oncology. He noted, "Our SenoVax™ program demonstrates that removing senescent cells can de-shield tumors and enable immune-mediated destruction. Beyond oncology, targeting senescence stands to restore youthful immune and regenerative function, a crucial part of our longevity vision." This focus on elder care dealings through scientific investigation expands the potential impacts of cancer therapies.
Dr. Lopes' Vision for the Future
Dr. Lopes expressed his enthusiasm about joining Immorta Bio, recognizing the opportunity to further explore the potentials of immunotherapy beyond traditional cancer treatments. This innovative approach highlights the foundational similarities between historical immunotherapies like pembrolizumab and the new direction aimed at boosting the immune response to tumors through senolytic pathways. "The concept behind SenoVax™—targeting senescent cells to enhance anti-tumor immunity—builds on the foundation established by checkpoint inhibitors like pembrolizumab. I am eager to help guide this innovative science toward patient care," said Dr. Lopes.
About Immorta Bio
Immorta Bio Inc. is a biotechnology leader with a dedication to longevity and the development of personalized therapies. The company's mission encompasses both SenoVax™—focusing on senolytic innovation—and StemCellRevivify™, which emphasizes personalized cellular rejuvenation and exosome technology. The company is gearing up for near-term clinical entry focused on advanced NSCLC treatments to push the boundaries of current therapeutic paradigms.
Frequently Asked Questions
What is the main focus of Immorta Bio?
Immorta Bio focuses on developing personalized therapies aimed at treating diseases of aging and addressing aging as a disease.
Who is Dr. Gilberto Lopes?
Dr. Gilberto Lopes is a renowned lung cancer expert and leader in immuno-oncology, known for his pivotal role in advancing checkpoint inhibitors.
What is SenoVax™?
SenoVax™ is Immorta Bio's first-in-class senolytic immunotherapy designed to target and eliminate senescent cells in tumors.
How does SenoVax™ work?
SenoVax™ works by training the immune system to selectively eliminate dysfunctional cells that contribute to tumor growth and resistance to therapy.
What is the significance of this appointment for Immorta Bio?
Dr. Lopes' appointment enhances Immorta Bio's leadership in lung cancer research while facilitating the development of next-generation immunotherapies.
